Treatment of systemic sclerosis with γ-interferon
- 1 May 1992
- journal article
- Published by Wiley in British Journal of Dermatology
- Vol. 126 (5) , 496-501
- https://doi.org/10.1111/j.1365-2133.1992.tb15122.x
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Interleukin 6Published by Springer Nature ,1990
- Recombinant human interleukin 6 (B‐cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1)FEBS Letters, 1988
- SpontaneousIn VitroRelease of Alveolar-Macrophage Cytokines after the Intratracheal Instillation of Bleomycin in Rats: Characterization and Kinetic StudiesAmerican Review of Respiratory Disease, 1988
- Interferon-α and interferon-γ reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in cultureBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1988
- SERUM LEVELS OF INTERLEUKIN-6 AND ACUTE PHASE RESPONSESThe Lancet, 1987
- A unifying model of the immunoregulatory role of the interferon system: Can interferon produce disease in humans?Clinical Immunology and Immunopathology, 1987
- Inhibition of fibroblast chemotaxis by recombinant human interferon γ and interferon αJournal of Cellular Physiology, 1987
- Type III Collagen Aminopropeptide Levels in Serum of Patients With Progressive Systemic SclerodermaJournal of Investigative Dermatology, 1986
- Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation.The Journal of Experimental Medicine, 1985
- Skin capillary changes in early systemic scleroderma. Electron microscopy and "in vitro" autoradiography with tritiated thymidineArchives of Dermatology, 1976